Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Ivy Abraham, MD, Garth Rauscher, PhD MPH, Anand Ashwin Patel, MD, Wendy Stock, MD, Maryam Zia, MD, Sushma Bharadwaj, MD, Koosha Paydary, MD, Maria Acevedo-Mendez, John P Galvin, MDMS,MPH, William Pearse, MD, Jessica K. Altman, John G. Quigley, Priya Rajakumar, MD, Melissa L. Larson, MD, Irum Khan, MD

Blood (2019) 134 (Supplement_1): 3413.

https://doi.org/10.1182/blood-2019-124974

Published: 2019

Journal Articles

Realized and Projected Cost Savings from the Introduction of Generic Imatinib, with Minimal Additional Savings to Payers through Formulary Management

Lisa Bloudek, John Brokars, MS, Campbell David, PharmD, MS, Dinara Makenbaeva, MD MBA

Blood (2018) 132 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2018-99-111966

Published: 2018

Journal Articles

Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective

Zheng-Yi Zhou, PhD, Kejal Parikh, Xinglei Chai, Ariel Rokito, Chuka Udeze, Jipan Xie, Amit Agarwal

Blood (2018) 132 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2018-99-112942

Published: 2018

Journal Articles

Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM)

Neil Hawkins, Karthik Ramasamy, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2018-99-111804

Published: 2018

Journal Articles

Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates

Lynn M. Malec, MD, Gilbert C. White, MD, Stacy E. Croteau, MD, Dunlei Cheng, PhD, Margaret V. Ragni, MD MPH

Blood (2018) 132 (Supplement 1): 2467.

https://doi.org/10.1182/blood-2018-99-115231

Published: 2018

Journal Articles

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Thomas Delea, MBA, MSIA, Nicholas Despiegel, Diana Boyko, Jordan Amdahl, Ze Cong, PhD MS, Jerald Radich, MD

Blood (2018) 132 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2018-99-115230

Published: 2018

Journal Articles

A Mixed Methods Approach to Generate Meaningful Change Estimates for the EORTC QLQ-MY20

Emre Yucel, PhD MSc, MBA, BSPharm, Andrew Trigg, MSc, Kate Sully, PhD, Amelia Harper, Nicola Bonner, MSc, Nina Shah, MD, Sumeet Panjabi, PhD, Kim Cocks

Blood (2018) 132 (Supplement 1): 5912.

https://doi.org/10.1182/blood-2018-99-116746

Published: 2018

Journal Articles

Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US

Abdalla Aly, PhD, Bela Bapat, MA, Saurabh Ray, PhD, Zhiyong Chen, PhD, Marc Botteman, MSc, MA

Blood (2017) 130 (Supplement 1): 3386.

https://doi.org/10.1182/blood.V130.Suppl_1.3386.3386

Published: 2017

Journal Articles

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective

Ivar S Jensen, MBA, Elizabeth Wu, Naomi Sacks, Philip Cyr, MPH, Karen Chung

Blood (2017) 130 (Supplement 1): 5615.

https://doi.org/10.1182/blood.V130.Suppl_1.5615.5615

Published: 2017

Journal Articles

Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, MD, Andrew J Klink, PhD MPH, Bruce Feinberg, DO, Michael McGuire, PharmD

Blood (2017) 130 (Supplement 1): 2188.

https://doi.org/10.1182/blood.V130.Suppl_1.2188.2188

Published: 2017

Journal Articles

Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities

Sikander Ailawadhi, Ryan D. Frank, Nicolette T. Chimato, Zahara Meghji, Raj Patel, MD, Prachi Jani, MD, Tanya S. Kakar, Mark A. Fiala, BS, Sonikpreet Aulakh, MD, David O. Hodge, MS, Taimur Sher, MD, Vivek Roy, MD, Prakash Vishnu, MD FACP, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 860.

https://doi.org/10.1182/blood.V130.Suppl_1.860.860

Published: 2017

Journal Articles

Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the US: A Retrospective Analysis of a Commercial Payer Database

Bruno C Medeiros, MD, Bhavik J Pandya, PharmD, Chi-Chang Chen, PhD, Eric S. Groves, MD PhD, Cat N. Bui, PhD, Laura Elise Horvath, MD, Rolin L. Wade, RpH, MS

Blood (2017) 130 (Supplement 1): 4694.

https://doi.org/10.1182/blood.V130.Suppl_1.4694.4694

Published: 2017

Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Eytan M. Stein, MD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Sherry Shi, MSc, Patrick Gagnon-Sanschagrin, BSc, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD

Blood (2016) 128 (22): 5929.

https://doi.org/10.1182/blood.V128.22.5929.5929

Published: 2016

Journal Articles

Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective

Ravi Potluri, Hitesh Bhandari, Sandip Ranjan, Clara Chen, PhD MS

Blood (2016) 128 (22): 2363.

https://doi.org/10.1182/blood.V128.22.2363.2363

Published: 2016

Journal Articles

Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)

Andrzej Jakubowiak, MD PhD, Istvan Matyas Majer, PhD, Ivan Houisse, MSc, Agnes Benedict, Marco Campioni, Sumeet Panjabi, Sikander Ailawadhi, MD

Blood (2016) 128 (22): 3582.

https://doi.org/10.1182/blood.V128.22.3582.3582

Published: 2016

Journal Articles

Risk Factors, Mortality, and Costs of Adults with Acute Myeloid Leukemia (AML) Admitted to the Intensive Care Unit (ICU): A Longitudinal Cohort Study

Anna B. Halpern, MD, Eva Culakova, PhD MS, Roland B. Walter, MD PhD MS, Gary H. Lyman, MD MPH

Blood (2015) 126 (23): 531.

https://doi.org/10.1182/blood.V126.23.531.531

Published: 2015

Journal Articles

Differences in Patients with Progressive Versus Non-Progressive AML, CLL, or NHL: Implications for Proposed Bundled Payment Strategies

Stacey Dacosta Byfield, PhD MPH, Nicole Engel-Nitz, PhD, Timothy Bancroft, PhD, Amy J Anderson, MS, Carolina Reyes, PhD, Arliene Ravelo, MPH, Sarika Ogale, PhD, May Chen, MD, Matthew J. Matasar, MD MS

Blood (2015) 126 (23): 4528.

https://doi.org/10.1182/blood.V126.23.4528.4528

Published: 2015

Journal Articles

Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective

Xiaoyan Li, PhD, Anjali Sharma, MD, Xinke Zhang, MS, Marco Campioni, PhD, Kelly Fust, MS, Junji Lin, PhD, Anju Parthan, PhD, Xuena Wang, PhD, Richard Zur, PhD, Karynsa Cetin, MPH, Melissa Eisen, MD

Blood (2015) 126 (23): 4461.

https://doi.org/10.1182/blood.V126.23.4461.4461

Published: 2015

Journal Articles

Cost of Bleeding-Related Episodes (BREs) in Adult Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States

Junji Lin, PhD, Xinke Zhang, MS, Xiaoyan Li, PhD, Ivy Altomare, MD, Jeffrey S Wasser, MD, Karynsa Cetin, MPH

Blood (2015) 126 (23): 3274.

https://doi.org/10.1182/blood.V126.23.3274.3274

Published: 2015

Journal Articles

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Richard T. Maziarz, MD, Annie Guerin, MSc, Genevieve Gauthier, MSc, Julie Heroux, MSc, Maryia Zhdanava, MSc, Eric Q Wu, PhD, Simu K Thomas, PhD, Lei Chen, MDPhD

Blood (2015) 126 (23): 872.

https://doi.org/10.1182/blood.V126.23.872.872

Published: 2015

NARROW

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Realized and Projected Cost Savings from the Introduction of Generic Imatinib, with Minimal Additional Savings to Payers through Formulary Management

Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective

Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM)

Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

A Mixed Methods Approach to Generate Meaningful Change Estimates for the EORTC QLQ-MY20

Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective

Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)

Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities

Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the US: A Retrospective Analysis of a Commercial Payer Database

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective

Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)

Risk Factors, Mortality, and Costs of Adults with Acute Myeloid Leukemia (AML) Admitted to the Intensive Care Unit (ICU): A Longitudinal Cohort Study

Differences in Patients with Progressive Versus Non-Progressive AML, CLL, or NHL: Implications for Proposed Bundled Payment Strategies

Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective

Cost of Bleeding-Related Episodes (BREs) in Adult Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only